GlassScriptPhysician profile
Jennifer Urch
NPI 1033995360
$5,062.13
in general payments reported to CMS, 2019-2025
32 companies · $3,669 in 2025
The $3,669 reported for 2025 was more than what 98% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $20.19 · 2024: $1,373 · 2025: $3,669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,062.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $809.70 | 2024-2025 | |
| Tg Therapeutics, INC. | $638.20 | 2024-2025 | |
| Emd Serono, INC. | $504.98 | 2024-2025 | |
| Biogen, INC. | $486.64 | 2024-2025 | Vumerity, Tysabri |
| Amgen INC. | $240.92 | 2024-2025 | Uplizna |
| Novartis Pharmaceuticals Corporation | $239.42 | 2024-2025 | |
| Axsome Therapeutics, INC. | $188.70 | 2024-2025 | Symbravo, Sunosi |
| Celgene Corporation | $179.21 | 2024-2025 | Zeposia |
| Genentech USA, INC. | $167.91 | 2024-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Argenx US, INC. | $153.83 | 2024-2025 | Vyvgart Hytrulo |
| Genzyme Corporation | $148.97 | 2024-2025 | |
| Ucb, INC. | $144.09 | 2024-2025 | Rystiggo, Zilbrysq |
| Cycle Pharmaceuticals INC | $125.41 | 2025 | Bafiertam, Tascenso Odt |
| Eisai INC. | $124.39 | 2024-2025 | |
| Pfizer INC. | $124.16 | 2023-2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $123.76 | 2024-2025 | Ultomiris |
| Abbott Laboratories | $88.23 | 2024 | Freestyle Libre 3 |
| Tempus Ai, INC | $85.85 | 2024 | |
| Vanda Pharmaceuticals INC. | $73.61 | 2024-2025 | Ponvory |
| Genentech, INC. | $66.90 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Mallinckrodt Hospital Products INC. | $64.17 | 2024-2025 | Acthar |
| Csl Behring | $56.20 | 2025 | Hizentra |
| Lilly USA, LLC | $45.12 | 2024 | Kisunla |
| Janssen Scientific Affairs, LLC | $24.16 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $23.24 | 2024 | Zeposia |
| Exact Sciences Corporation | $22.91 | 2024 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $22.82 | 2025 | Ajovy |
| Jazz Pharmaceuticals INC. | $22.49 | 2024 | |
| Ani Pharmaceuticals, INC. | $19.60 | 2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $16.49 | 2024 | Wegovy |
| Neurelis, INC. | $15.60 | 2025 | Valtoco |
| Lundbeck LLC | $14.45 | 2025 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Urch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.